Campbell Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-6,630
Closed -$220K 72
2023
Q3
$220K Buy
6,630
+307
+5% +$10.9K 0.03% 68
2023
Q2
$232K Buy
6,323
+2
+0% +$78 0.03% 61
2023
Q1
$258K Sell
6,321
-177
-3% -$7.64K 0.03% 57
2022
Q4
$333K Sell
6,498
-31
-0.5% -$1.49K 0.05% 45
2022
Q3
$286K Buy
6,529
+1,045
+19% +$50.8K 0.04% 51
2022
Q2
$288K Sell
5,484
-337
-6% -$17.2K 0.04% 39
2022
Q1
$301K Buy
5,821
+2
+0% +$104 0.04% 52
2021
Q4
$344K Buy
5,819
+1
+0% +$50 0.04% 50
2021
Q3
$250K Buy
5,818
+2
+0% +$89 0.03% 62
2021
Q2
$228K Buy
5,816
+2
+0% +$78 0.03% 60
2021
Q1
$211K Buy
5,814
+2
+0% +$71 0.03% 66
2020
Q4
$214K Sell
5,812
-259
-4% -$9.5K 0.03% 62
2020
Q3
$211K Sell
6,071
-75
-1% -$2.63K 0.03% 56
2020
Q2
$191K Sell
6,146
-619
-9% -$21K 0.03% 56
2020
Q1
$209K Sell
6,765
-1,279
-16% -$43.6K 0.05% 44
2019
Q4
$299K Sell
8,044
-98
-1% -$3.49K 0.06% 45
2019
Q3
$278K Sell
8,142
-844
-9% -$30.7K 0.06% 47
2019
Q2
$369K Buy
8,986
+302
+3% +$12K 0.09% 35
2019
Q1
$350K Buy
8,684
+558
+7% +$22.3K 0.09% 33
2018
Q4
$337K Buy
+8,126
New +$337K 0.1% 30

Other funds holding PFE

Campbell Wealth Management's PFE Position: Q4 2023 in Review

Campbell Wealth Management sold out of Pfizer (PFE) in Q4 2023, closing a stake of 6,630 shares — an estimated $220K sold.

Campbell Wealth Management first reported a position in PFE in Q4 2018 and held it in 20 quarters. The position peaked at $369K in Q2 2019. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

  • Campbell Wealth Management reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
  • Campbell Wealth Management sold 6,630 Pfizer shares in Q4 2023, an estimated $220K.
  • Campbell Wealth Management first reported a position in Pfizer in Q4 2018 and held it in 20 quarters.
  • Campbell Wealth Management's Pfizer position peaked at $369K in Q2 2019.
  • 2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Campbell Wealth Management's 13F filing for Q4 2023, filed 8 Feb 2024.